XL228
XL228 is a multi-targeted tyrosine kinase inhibitor with IC50s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, IGF-1R, Src and Lyn, respectively.
Product Specifications
CAS Number
898280-07-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Aurora Kinase; Bcr-Abl; IGF-1R; Src
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/XL228.html
Purity
99.64
Solubility
DMSO : ≥ 83.33 mg/mL
Smiles
CN1CCN(C2=CC(NC3=NNC(C4CC4)=C3)=NC(NCC5=CC(C(C)C)=NO5)=N2)CC1
Molecular Formula
C22H31N9O
Molecular Weight
437.54
Precautions
H302, H315, H319
References & Citations
[1]Cortes J, et al. Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation. Blood 2008 112:3232|[2]Douglas O, et al. Abstract C192: Characterization of the target profile of XL228, a multi‐targeted protein kinase inhibitor in phase 1 clinical development. Mol Cancer Ther 2009;8 (12 Suppl) :C192.|[3]Shah N, et al. Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228. Blood 2007 110:474
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
Aurora A
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-H953610-25MG 25 mg
(5R)-5-Hydroxy-3-oxo-6-(benzyloxy)-hexanoic Acid tert-Butyl Ester
Sign In for Pricing
View Details 
BNCB0149-500 1x 500 µL
CD106 / VCAM1 (1.4C3), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TP304426M 100 µg
Rabex5 (RABGEF1) (NM_014504) Human Recombinant Protein
Sign In for Pricing
View Details 